APA (7th ed.) Citation

K, H., S, S., LFV, W., T, D., A, K., F, K., . . . V, H. (2026). Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial. European journal of cancer (Oxford, England : 1990), 232, 116133. https://doi.org/10.1016/j.ejca.2025.116133

Chicago Style (17th ed.) Citation

K, Heinrich, et al. "Impact of Sex on Efficacy and Safety of 1st-line Treatment with FOLFIRI Plus Cetuximab or Bevacizumab in RAS/BRAF Wildtype Metastatic Colorectal Cancer - A Subgroup Analysis of the FIRE-3 (AIO KRK-0306) Trial." European Journal of Cancer (Oxford, England : 1990) 232 (2026): 116133. https://doi.org/10.1016/j.ejca.2025.116133.

MLA (9th ed.) Citation

K, Heinrich, et al. "Impact of Sex on Efficacy and Safety of 1st-line Treatment with FOLFIRI Plus Cetuximab or Bevacizumab in RAS/BRAF Wildtype Metastatic Colorectal Cancer - A Subgroup Analysis of the FIRE-3 (AIO KRK-0306) Trial." European Journal of Cancer (Oxford, England : 1990), vol. 232, 2026, p. 116133, https://doi.org/10.1016/j.ejca.2025.116133.